Abstract
Immunohistochemical analysis of paired tumor and normal tissue specimens revealed that the expression and cytoplasmic abundance of the RNA-binding protein HuR increased with malignancy, particularly in colon carcinomas. Interventions to modulate HuR expression in human RKO colon cancer cells altered gene expression profiles and identified β-catenin mRNA as a novel HuR target. Subcutaneous injection of HuR-overexpressing RKO cells into nude mice produced significantly larger tumors than those arising from control populations; conversely, RKO cells expressing reduced HuR through small interference RNA- or antisense HuR-based approaches developed significantly more slowly. We propose that HuR-regulated target mRNA expression contributes to colon cancer growth. Our results suggest a pivotal function for HuR in colon carcinogenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- CR:
-
coding region
- ELAV:
-
embryonic lethal abnormal vision
- REMSA:
-
RNA electrophoretic mobility-shift assay
- UTR:
-
untranslated region
References
Antic D and Keene JD . (1997). Am. J. Hum. Genet., 61, 273–278.
Atasoy U, Watson J, Patel D and Keene JD . (1998). J. Cell Sci., 111, 3145–3156.
Balkwill F . (2002). Cytokine Growth Factor Rev., 13, 135–141.
Blaxall BC, Dwyer-Nield LD, Bauer AK, Bohlmeyer TJ, Malkinson AM and Port JD . (2000). Mol. Carcinogen., 28, 76–83.
Bosher JM and Labouesse M . (2000). Nat. Cell Biol., 2, E31–E36.
Brennan CM, Gallouzi IE and Steitz JA . (2000). J. Cell. Biol., 151, 1–14.
Brennan CM and Steitz JA . (2001). Cell. Mol. Life Sci., 58, 266–277.
Cheadle C, Vawter MP, Freed WJ and Becker KG . (2003). J. Mol. Diagn., 5, 73–81.
Chen CY, Xu N and Shyu A-B . (2002). Mol. Cell. Biol., 22, 7268–7278.
Dalmau J, Furneaux HM, Gralla RJ, Kris MG and Posner JB . (1990). Ann. Neurol., 27, 544–552.
Dixon DA, Tolley ND, King PH, Nabors LB, McIntyre TM, Zimmerman GA and Prescott SM . (2001). J. Clin. Invest., 108, 1657–1665.
Fan XC and Steitz JA . (1998a). Proc. Natl. Acad. Sci. USA, 95, 15293–15298.
Fan XC and Steitz JA . (1998b). EMBO J., 17, 3448–3460.
Fan J, Yang X, Wang W, Wood III WH, Becker KG and Gorospe M . (2002). Proc. Natl. Acad. Sci. USA, 99, 10611–10616.
Fearon ER and Vogelstein B . (1990). Cell, 61, 759–767.
Folkman J . (1995). Nat. Med., 1, 27–31.
Gorospe M, Wang X and Holbrook NJ . (1998). Mol. Cell. Biol., 18, 1400–1407.
Jooss KU and Muller R . (1995). Oncogene, 10, 603–608.
Joseph B, Orlian M and Furneaux H . (1998). J. Biol. Chem., 273, 20511–20516.
Keene JD . (1999). Proc. Natl. Acad. Sci. USA, 96, 5–7.
Keene JD and Tenenbaum SA . (2002). Mol. Cell, 9, 1161–1167.
Laird NM and Ware JH . (1982). Biometrics, 38, 963–974.
Levine TD, Gao F, King PH, Andrews LG and Keene JD . (1993). Mol. Cell. Biol., 13, 3494–3504.
Levy NS, Chung S, Furneaux H and Levy AP . (1998). J. Biol. Chem., 273, 6417–6423.
Morrell CH, Pearson JD and Brant LJ . (1997). Am. Statistician, 51, 338–343.
Nabors LB, Gillespie GY, Harkins L and King PH . (2001). Cancer Res., 61, 2154–2161.
Sager R . (1997). Proc. Natl. Acad. Sci. USA, 94, 952–955.
SAS Institute Inc.. 1999. SAS/STAT® User's Guide, Version 8, SAS Institute Inc.: Cary, NC.
Szabo A, Dalmau J, Manley G, Rosenfeld M, Wong E, Henson J, Posner JB and Furneaux HM . (1991). Cell, 67, 325–333.
Tenenbaum SA, Carson CC, Lager PJ and Keene JD . (2000). Proc. Natl. Acad. Sci. USA, 97, 14085–14090.
Vawter MP, Barrett T, Cheadle C, Sokolov BP, Wood WH, Donovan D, Webster M, Freed WJ and Becker KG . (2001). Brain Res. Bull., 55, 641–650.
Wang W, Caldwell MC, Lin S, Furneaux H and Gorospe M . (2000a). EMBO J., 19, 2340–2350.
Wang W, Fan J, Yang X, Fürer S, López de Silanes I, von Kobbe C, Guo J, Georas SN, Foufelle F, Hardie DG, Carling D and Gorospe M . (2002). Mol. Cell. Biol., 22, 3425–3436.
Wang W, Furneaux H, Cheng H, Caldwell MC, Hutter D, Liu Y, Holbrook NJ and Gorospe M . (2000b). Mol. Cell. Biol., 20, 760–769.
Wang W, Yang X, Cristofalo VJ, Holbrook NJ and Gorospe M . (2001). Mol. Cell. Biol., 21, 5889–5898.
Wong NA and Pignatelli M . (2002). Am. J. Pathol., 160, 389–401.
Acknowledgements
We thank MB Kastan for the RKO cells, S Galbán, M Jr Ware, J Robinson, C Galbán, and J Alsruhe for assistance with experimental procedures, and KG Becker and C Cheadle for providing cDNA arrays and guidance in their analysis. We are grateful to our colleagues PJ Morin and DL Longo for critical reading of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
de Silanes, I., Fan, J., Yang, X. et al. Role of the RNA-binding protein HuR in colon carcinogenesis. Oncogene 22, 7146–7154 (2003). https://doi.org/10.1038/sj.onc.1206862
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206862
Keywords
This article is cited by
-
Exosomal circSPIRE1 mediates glycosylation of E-cadherin to suppress metastasis of renal cell carcinoma
Oncogene (2023)
-
LncGMDS-AS1 promotes the tumorigenesis of colorectal cancer through HuR-STAT3/Wnt axis
Cell Death & Disease (2023)
-
Circular RNA MTCL1 promotes advanced laryngeal squamous cell carcinoma progression by inhibiting C1QBP ubiquitin degradation and mediating beta-catenin activation
Molecular Cancer (2022)
-
Molecular mechanism of miR-34b-5p and RNA binding protein HuR binding to lncRNA OIP5-AS1 in colon cancer cells
Cancer Gene Therapy (2022)
-
EIF4A3-induced circCCNB1 (hsa_circ_0001495) promotes glioma progression by elevating CCND1 through interacting miR-516b-5p and HuR
Metabolic Brain Disease (2022)